| Similar Articles |
|---|
 |
The Motley Fool
December 18, 2008
Brian Orelli |
A Diagnostic Tongue Twister Back-scratch fever between Abbott and Isis.   |
The Motley Fool
July 14, 2009
Brian Orelli |
Diagnosing a Personalized Partnership Abbott and Glaxo hook up on diagnostics. |
The Motley Fool
September 18, 2007
Brian Orelli |
Another Partnership for Personalized Medicine Celera gets a contract to design a companion diagnostic test for Merck. Investors, take note. |
The Motley Fool
January 23, 2007
Ralph Casale |
Win-Win for Abbott and GE? Abbott trades its medical diagnostics segment for cold hard cash. Will shareholders see this deal as a win-win scenario? Investors, take note. |
The Motley Fool
August 22, 2008
Brian Orelli |
Abbott Tries a Crash Diet The health-care conglomerate is cutting jobs in its diagnostic testing division. |
BusinessWeek
January 29, 2007
Michael Arndt |
Abbot Labs: Diagnosis: Shrewd Moves Abbott Laboratories has announced that it is selling about two-thirds of its $4 billion diagnostics business to buy more medical products outfits to help boost overall sales and profits by at least 10% a year into the next decade. |
The Motley Fool
July 19, 2007
Brian Lawler |
Abbott on Top Abbott announces second-quarter financial results. Shares of Abbott aren't particularly expensive, considering the growth potential for its top compounds and its strong drug pipeline with compounds in development for several blockbuster indications. |
Bio-IT World
February 2006
Kevin Davies |
Celera Drops Drugs for Diagnostics The company that raced to sequence the human genome, ditched its flamboyant CEO and database subscription model to become a drug development company, has decided to change course yet again. |
The Motley Fool
June 20, 2008
Brian Orelli |
Live From Bio: Personalized Medicine The movement is chugging along thanks to diagnostics. |
The Motley Fool
August 28, 2009
Brian Orelli |
Abbott Signs Up Another One Abbott announces that it has set up a partnership with Pfizer to run tests on Pfizer's new drug. |
The Motley Fool
September 28, 2007
Brian Orelli |
Side Effects No Match for This Tag Team Seven large drugmakers have come together to try and find genetic variations that cause medications to have serious side effects in some patients, but not in others. |
The Motley Fool
June 29, 2010
Brian Orelli |
Redeploying Capital? Investors Hope So. Selling a business unit won't help Abbott Labs diversify. |
The Motley Fool
March 30, 2007
Ralph Casale |
Another Genetic Sequencer Gobbled Up Roche buys out second-generation sequencer 454 Life Sciences. Investors, take note. |
Pharmaceutical Executive
May 1, 2006
Sunshine K. Mugrabi |
Back Page: Risk Assessment New thinking and diagnostic tests may change how statins are marketed and prescribed. |
The Motley Fool
January 30, 2007
Brian Lawler |
Is Bigger Better for Abbott Labs? Abbott continues its transformation into a more focused pharmaceutical powerhouse. But shares of this pharmaceutical aren't exactly cheap. |
The Motley Fool
October 15, 2008
Brian Orelli |
Abbott's Stents Aren't (That) Important Abbott's shareholders shouldn't be too focused on drug-eluting stents. |
Chemistry World
October 25, 2007
Arthur Rogers |
European Ethical Guidelines Weigh in Against Mail Order Genetic Tests The Council of Europe (CoE) has come out against mail-order and over-the-counter genetic tests in new ethical guidelines that seek to address dilemmas faced by health services without hobbling scientific progress towards 'personalized medicine'. |
The Motley Fool
September 28, 2009
Rick Aristotle Munarriz |
Abbott Labs Looks Less Lopsided Abbott Labs' $6.6 billion purchase of Solvay's pharmaceuticals business is just what the doctor ordered. |
The Motley Fool
October 18, 2006
Brian Lawler |
Is a Buyback the Best Abbott Can Do? Abbott Labs may be out of ideas for its cash. Investors, take note. |
The Motley Fool
July 29, 2010
Brian Orelli |
Is Abbott a Buy? Whether or not Abbott is a buy depends on management's ability to transition the company. |
The Motley Fool
September 5, 2008
Brian Orelli |
Zimmer Fortifies Its Spine The medical-device maker is buying Abbott's spine business. |
Bio-IT World
March 2006
Michael A. Greeley |
The Theranostics Promise A huge amount of discovery and clinical development for new drugs involves clinical trials that include companion diagnostic tests. These theranostic tests are poised to become a promising market for entrepreneurs, though challenges -- such as patent issues -- remain. |
Bio-IT World
January 21, 2005
Kevin Davies |
A Vision for iScience Applied Biosystems president Catherine Burzik discusses integrated science, lab technology, and running a $2B business. |
The Motley Fool
June 13, 2008
Brian Orelli |
China Medical Passes the Test China Medical's revenue was up an impressive 74% year over year. |
The Motley Fool
October 20, 2011
Brian Orelli |
Mini J&J? I Guess Not Abbott says it plans to split in two: drugs in one company, everything else in the other. |
The Motley Fool
August 4, 2010
Matt Koppenheffer |
How Much Is Abbott Labs Worth? Is Abbott Labs' stock on sale? |
The Motley Fool
January 25, 2006
Stephen D. Simpson |
Abbott Wins No matter what Boston Scientific does with Guidant, Abbott looks like a winner. This stock might not offer a rocket ride the way smaller biotechs and med-tech companies do, but at today's prices, at least you won't have to worry about a fiery re-entry. |
Fast Company
David Lumb |
Sites That Sell Cancer Gene Tests Don't Tell Customers The Whole Story, Study Finds Consumer tests that analyze DNA from tumors in order to help personalize a patient's treatment are in something of a Wild West period. |
The Motley Fool
July 17, 2008
Brian Orelli |
Investors Yawn at Abbott Labs' Growth Abbott Labs may be firing on all cylinders, but investors were less than impressed with its earnings release |
Bio-IT World
August 18, 2004 |
Little News Is Good News Hopes that a burst of high-flying IPOs would fan investor interest in biotechnology were dashed in Q2, as several companies had to accept much lower prices than anticipated. |
The Motley Fool
October 12, 2004
Brian Gorman |
Abbott's Healthy Diet Is the company's push into nutritional supplements a wise move? |
The Motley Fool
April 19, 2006
Stephen D. Simpson |
Abbott Gets By Will the acquisition of Guidant's vascular business kick-start this story? Abbott has shown a pretty reliable trend of getting cheap enough to buy at least once a year. Of course, the downside to that is that the stock really hasn't gone anywhere in those seven years. |
The Motley Fool
February 24, 2011
Brian Orelli |
Abbott: 1, Johnson & Johnson: 0 -- For Now Abbott Labs got a ruling overturned yesterday that would have cost the company $1.8 billion, yet investors let shares slip down 1%. |
The Motley Fool
January 22, 2009
Brian Orelli |
Abbott Labs Thumbs Nose at Recession On a GAAP basis, Abbott Labs fourth-quarter earnings per share were up a whopping 27%, and even better, the double-digit increases don't look like they're going to stop anytime soon. |
Chemistry World
May 21, 2014
Phillip Broadwith |
Abbott to buy Chile's CFR for $3bn The move will bolster Abbott's position in the rapidly growing markets of Latin America. |
The Motley Fool
November 13, 2009
Brian Orelli |
Abbott: Brave or Stupid? Abbott Labs announces the acquisition of PanGenetics' pain drug PG110, which is still in phase 1 trials. |
Bio-IT World
May 2006 |
News Blast Aids Action... Oxford Universal... Myriad Options... |
The Motley Fool
October 11, 2010
Brian Orelli |
What Meridia's Demise Means for Arena, VIVUS, and Orexigen Safety first ... and second ... and third... |
The Motley Fool
November 15, 2011
Dan Caplinger |
Has Abbott Labs Become the Perfect Stock? For long-term investors, Abbott's continuing devotion to up its dividend -- its streak now stands at 39 years -- makes a compelling reason to hold onto your shares. |
The Motley Fool
January 27, 2011
Brian Orelli |
Abbott Labs: Growth in All the Wrong Places Abbott's a solid company with solid dividend and growth potential in the near term. But investors need to be careful extrapolating that growth out. |
AskMen.com
Jacob Franek |
Genetic Testing Every day the prospect of individualized genetic testing is slowly becoming commonplace, and certain questions about genetic testing are apparent: What kinds of tests are available? Where can I get them? How accurate are they? And what are the costs? |
The Motley Fool
March 31, 2011
David Williamson |
Embarking on a Profitable Quest Quest Diagnostics has been busy, snapping up a pair of smaller players and seeing its share price recover to near 52-week highs. Let's take a look at what these acquisitions mean going forward. |
Managed Care
November 2006
Maureen Glabman |
Genetic Testing: Major Opportunity, Major Problems Whether a person is likely to develop diabetes, cancer, schizophrenia, or stroke will be reasonably well predicted, and tests can also determine whether a patient will respond to a given therapy. That's the good part. |
The Motley Fool
September 24, 2010
Brian Orelli |
Good Deal? Bad Deal? Hard to Tell. Investors are in the dark on Abbott Labs' license of Reata Pharmaceuticals' kidney failure drug bardoxolone for $450 million up front. |
The Motley Fool
November 8, 2011
Brian Wilson |
2 Health-Care Stocks for Times of Uncertainty Just because Abbott and Johnson & Johnson don't undertake as much risk as other health-care giants doesn't mean that shareholders won't see impressive growth in revenues. |
The Motley Fool
April 8, 2005
Stephen D. Simpson |
Abbott Hopes to Maxx Out Abbott announced FDA approval to begin a pivotal trial for its drug-eluting stent. Will this be too little too late for shareholders, or a true dark horse? |
The Motley Fool
June 22, 2011
Brian Orelli |
In-Licensing to the Rescue Abbott's latest deal could help shore things up. |
The Motley Fool
July 13, 2005
Stephen D. Simpson |
Is Abbott's Ailment Serious? There's room for improvement at Abbott Labs, but this is one solid and broadly diversified company. Shares aren't a screaming bargain, but the current price-to-earnings ratio really isn't out of line with history. |
BusinessWeek
September 5, 2005
Capell & Arndt |
Drugs Get Smart Future medicines will more effectively target what ails you by tailoring treatment to your specific genetic profile. Personalized medicine will also help prevent another Vioxx. |
The Motley Fool
January 19, 2011
Brian Orelli |
A Painfully Protracted Partner Depomed is in a bind. |
